martes, 22 de noviembre de 2016

Tick-Borne Relapsing Fever, Southern Spain, 2004–2015 - Volume 22, Number 12—December 2016 - Emerging Infectious Disease journal - CDC

Tick-Borne Relapsing Fever, Southern Spain, 2004–2015 - Volume 22, Number 12—December 2016 - Emerging Infectious Disease journal - CDC

Volume 22, Number 12—December 2016

Letter

Tick-Borne Relapsing Fever, Southern Spain, 2004–2015

On This Page

Figures

Altmetric

    Article has an altmetric score of 3
To the Editor: Surveillance data indicate that tickborne diseases are substantial and increasing global public health problems (1). Various pathogens, including viruses, bacteria, protozoa, and helminthes, are transmitted from ticks to vertebrates (2). Tick-borne relapsing fever (TBRF) is a zoonosis that is enzootic in many countries (3). This illness is caused by >10 Borrelia species and is transmitted to humans through the bite of soft ticks of the genus Ornithodoros (3).
Currently, TBRF is endemic in various foci around the world. However, few TBRF cases are reported in the United States, and in most western European countries, such as Spain, TBRF occurs sporadically, usually after opportunistic infections in persons exposed to ticks (3,4). Many authors consider TBRF to be underrecognized and underreported (5). Although molecular tools such as PCR can dramatically improve diagnosis of this illness, methods used to diagnose TBRF have changed little since the discovery of the spirochete.
Thumbnail of Spirochetes on a thick peripheral blood smear from a patient with tick-borne relapsing fever, southern Spain, 2004–2015.
Figure. Spirochetes on a thick peripheral blood smear from a patient with tick-borne relapsing fever, southern Spain, 2004–2015. Original magnification ×1,000.
To evaluate the prevalence and clinical features of TBRF in a rural area of southern Spain, we retrospectively reviewed clinical data for all patients ≥14 years of age who sought care for TBRF during January 2004–December 2015 at Hospital de la Merced, a county hospital in Seville, Spain. We defined a case of TBRF as detection of spirochetes on thin- or thick-blood smears or in cerebrospinal fluid (CSF) samples by using conventional microscopy after Giemsa or Wright staining (Figure).
Of 75 patients, 42 (56%) were male and 33 (44%) were female. Mean age was 33 (range 14–72) years. Nine (12%) patients reported tick bites. The most common symptoms were fever (64 [85.3%] patients), headache (41 [54.6%]), vomiting (26 [34.6%]), muscle ache (22 [29.3%]), and abdominal pain (21 [28%]). At the time of the hospital visit, 9 (12%) patients had signs and symptoms suggesting meningeal involvement; 3 (4%) others had clear meningeal signs. These 12 patients underwent lumbar puncture, and CSF abnormalities were found in the 3 (4%) patients with meningismus. Spirochetes were found in the CSF sample of 1 patient. Of the total 75 patients, this patient was the only 1 with spirochetes, and no patient had facial palsy or other neurologic manifestation. The main laboratory findings were elevated C-reactive protein, found in 74 (98.6%) patients; thrombocytopenia, found in 67 (89.3%); and anemia, found in 37 (49.3%).
Preferred treatment was oral doxycycline, which was used for a mean duration of 10 (range 7.3–14) days in 55 patients (73.3%). Among 3 TBRF patients with neurologic involvement, 1 was treated with penicillin G (3 million units/4 h for 10 d), and 2 were treated with ceftriaxone (2 g/d for 14 d). Jarisch-Herxheimer reaction occurred in 7 (9.3%) patients, none of whom had meningitis. All patients recovered completely.
Currently, TBRF is widely distributed in various foci around the world. In much of sub-Saharan Africa, TBRF is associated with a high number of illnesses and deaths. Indeed, it is reportedly the most common bacterial infection from Senegal and is listed among the 10 leading causes of death in children <5 a="" age="" class="tp-link-policy" href="http://wwwnc.cdc.gov/eid/article/22/12/16-0870_article#r6" in="" of="" style="color: #075290;" tanzania="" title="6" years="">6
). Elsewhere in the world, this infection is regarded as rare. Although TBRF borreliosis occurs infrequently in developed countries, our study highlights TBRF endemicity in an area of southern Spain.
Reports on TBRF in Spain are scarce. The only previous study involving numerous cases of TBRF in Spain (7) described 230 cases and was published in the early 20th century. That research showed that, although disease caused by B. hispanica is less severe than that of other TBRFs, ≈5% of patients had neurologic complications. In our study, 3 (4%) patients had meningitis caused by TBRF borreliosis, a finding that accords with the previous report.
A recent study conducted among children in southern Spain (8) identified 9 cases of TBRF during a 10-year period. Two children, 3 and 5 years of age, had meningeal involvement but no other neurologic complication. Similar to observations in our study, Jarisch-Herxheimer reaction was infrequent, occurring in only 1 of the 9 children.
Neurologic complications are well known features of infection with 2 spirochetes, B. burgdorferi and Treponema pallidum (9). Nevertheless, little is published and known about the predilection of TBRF borreliosis to infect the nervous system. One of the few studies reviewing neurologic involvement of TBRF borreliosis reported that B. turicatae and B. duttonii, the agents of TBRF in southwestern North America and sub-Saharan Africa, respectively, cause neurologic involvement as often as B. burgdorferi causes Lyme disease (10).
Our study confirms that TBRF is an endemic, underreported disease in many countries and is common in southern Spain. Although the disease caused by B. hispanica is among the less severe illnesses caused by the relapsing fever group, serious neurologic complications can occur. With increasing globalization, physicians will likely see increased numbers of travel-related infections and will face imported and emerging TBRF cases.
Luis Castilla-Guerra1Comments to Author , Jorge Marín-Martín1, and Miguel Angel Colmenero-Camacho
Author affiliations: Hospital Universitario Virgen Macarena, Seville, Spain (L. Castilla-Guerra, M.A. Colmenero-Camacho)Universidad de Sevilla, Seville (L. Castilla-Guerra, M.A. Colmenero-Camacho)Hospital de la Merced, Seville (J. Marín-Martín)

References

  1. Hook SANelson CAMead PSUSU.S. public’s experience with ticks and tick-borne diseases: results from national HealthStyles surveys. Ticks Tick Borne Dis. 2015;6:4838DOIPubMed
  2. Baneth GTick-borne infections of animals and humans: a common ground. Int J Parasitol2014;44:5916DOIPubMed
  3. Dworkin MSSchwan TGAnderson DE JrBorchardt SMTick-borne relapsing fever. Infect Dis Clin North Am2008;22:44968DOIPubMed
  4. Rebaudet SParola PEpidemiology of relapsing fever borreliosis in Europe. FEMS Immunol Med Microbiol2006;48:115DOIPubMed
  5. Dworkin MSShoemaker PCFritz CLDowell MEAnderson DE JrThe epidemiology of tick-borne relapsing fever in the United States. Am J Trop Med Hyg2002;66:7538.PubMed
  6. Cutler SJRelapsing fever—a forgotten disease revealed. J Appl Microbiol2010;108:111522DOIPubMed
  7. Mas de Ayala IEstudio clınico de la fiebre recurrente española (230. observaciones). Medicina Paıses Cálidos1931;4:36989.
  8. Croche Santander BSánchez Carrión ACampos EToro CMarcos LVargas JC, et al. Tick-borne relapsing fever in a rural area of southern Spain. An Pediatr (Barc)2015;82:e737DOIPubMed
  9. Halperin JJA tale of two spirochetes: Lyme disease and syphilis. Neurol Clin2010;28:27791DOIPubMed
  10. Cadavid DBarbour AGNeuroborreliosis during relapsing fever: review of the clinical manifestations, pathology, and treatment of infections in humans and experimental animals. Clin Infect Dis1998;26:15164DOIPubMed

Figure

Suggested citation for this article: Castilla-Guerra L, Marín-Martín J, Colmenero-Camacho MA. Tick-borne relapsing fever, southern Spain, 2004–2015. Emerg Infect Dis. 2016 Dec [date cited]. http://dx.doi.org/10.3201/eid2212.160870
DOI: 10.3201/eid2212.160870

1These authors contributed equally to this article.

No hay comentarios:

Publicar un comentario